Résumé
Calcineurin inhibitors (CNI), including oral cyclosporin A and tacrolimus, are intensive immunosuppressants that are extensively used in the treatment of rheumatic and immunologic diseases in China. CNI selectively inhibit the activation and proliferation of T lymphocytes and the transcription of cytokines [such as tumor necrosis factor-α, interleukin (IL)-6, and IL-17] through inhibiting the activation of calcineurin in cells and reducing the release of IL-2. To standardize the use of CNI in the field of rheumatic and immunologic diseases, this consensus statement was developed by the National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital), in conjunction with the Chinese Association of Rheumatology and Immunology Physicians, the Chinese Research Hospital Association, the Rheumatology and Immunology Professional Committee, and the Chinese Association of Rehabilitation Medicine. The 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence was used to rate the quality of the evidence and the strength of the recommendations, and the RIGHT (Reporting Items for practice Guidelines in HealThcare) checklist was followed to report the consensus. The consensus offers recommendations addressing nine clinical challenges to Chinese clinicians. The primary objective of this consensus is to deliver scientific and detailed guidance on CNI for Chinese clinicians, and to improve the quality of patient-centered medical services.
Sujets)
Humains , Inhibiteurs de la calcineurine/pharmacologie , Immunosuppresseurs/usage thérapeutique , Tacrolimus/pharmacologie , Lymphocytes T , Maladies du système immunitaire , Rhumatismes/traitement médicamenteuxRésumé
Las nuevas estrategias, que incluyen el diagnóstico y el tratamiento tempranos, el enfoque de tratamiento dirigido a un objetivo, la remisión como ese objetivo principal del tratamiento, la participación de los pacientes en las decisiones terapéuticas, junto con el desarrollo de nuevos tratamientos efectivos, han cambiado las expectativas de los reumatólogos y de los pacientes con enfermedades reumáticas. Todavía existen, sin embargo, importantes desafíos tales como la seguridad a largo plazo de los tratamientos actuales y poder escoger tratamientos más individualizados y eficaces, de forma tal de elegir el mejor tratamiento para cada paciente. El futuro, como en el resto de la medicina, probablemente sea la prevención del desarrollo de enfermedades reumáticas. Discutiremos estos temas en esta revisión. (AU)
New strategies, including early diagnosis and treatment, targeted therapy, remission as the main objective of treatment, patient involvement in therapeutic decision-making, and the development of new effective therapies, have changed the expectations of rheumatologists and patients with rheumatic diseases.There are still serious challenges, such as the long-term safety of current treatments and the ability to make more individualized and effective treatments to choose the best treatment for each patient. The future, as that of the whole of medical science, will probably lie in preventing the development of rheumatic diseases. We will discuss these issues in this review. (AU)
Sujets)
Humains , Rhumatismes/diagnostic , Rhumatismes/prévention et contrôle , Rhumatismes/traitement médicamenteux , Participation des patients , Induction de rémission/méthodes , Diagnostic précoce , Médecine de précision/tendances , Pharmacovigilance , Traitement précoce ciblé/méthodesRésumé
Tofacitinib is a Janus kinase inhibitor and can block the Janus kinase-signal transducer and activator of transcription signal transduction pathway and reduce the production and release of a variety of cytokines. It has great potential in the treatment of various rheumatic diseases with a rapid onset of action and can reduce corticosteroid dependence and related adverse events. The therapeutic effect of tofacitinib in adult patients has been confirmed, and it has been increasingly used in pediatric patients in recent years. This article reviews the clinical application of tofacitinib in the treatment of pediatric autoimmune diseases.
Sujets)
Adulte , Enfant , Humains , Janus kinases/métabolisme , Pipéridines/usage thérapeutique , Inhibiteurs de protéines kinases/usage thérapeutique , Pyrimidines/usage thérapeutique , Rhumatismes/traitement médicamenteuxRésumé
La evidencia científica presente en la literatura indica que el cannabis puede ser utilizado con fines terapéuticos para tratar distintas afecciones odontológicas. Dado el acceso sencillo a la cavidad bucal, las distintas formulaciones de cannabis pueden aplicarse de forma tópica. La aplicación local de dosis bajas de cannabis ha demostrado alta efectividad para tratar distintas afecciones bucales, constituyendo un tratamiento seguro con baja probabilidad de generar repercusiones sistémicas indeseadas. En la actualidad, está siendo incorporado a materiales convencionales de uso e higiene odontológica con la finalidad de aprovechar sus efectos terapéuticos. El cannabis tiene múltiples usos en odontología: como componen-te de enjuagues bucales y soluciones para la desinfección de conductos radiculares, en tratamientos de trastornos de ansiedad bucal, como complemento en terapias oncológicas, como analgésico para atenuar el dolor inflamatorio y el neuropático, como miorrelajante y condroprotector para tratar trastornos de articulación témporomandibular (ATM) y bruxismo, como osteomodulador para el tratamiento de patologías que comprometen la integridad ósea, como la enfermedad periodontal y la osteoporosis, y para la cicatrización ósea asociada a fracturas, extracciones dentarias e implantes, y como inmunomodulador con potencial terapéutico para tratar patologías autoinmunes como las enfermedades reumáticas. El trata-miento local con cannabis es efectivo, bien tolerado por el paciente y con pocos efectos adversos. Por lo tanto, se puede concluir que el cannabis aporta un enorme abanico de posibilidades terapéuticas para tratar distintas afecciones odontológicas, aunque aún se requiere mayor cantidad de estudios científicos que avalen su utilización en cada situación fisiopatológica particular (AU)
The scientific evidence present in the literature indicates that cannabis can be used for therapeutic purposes to treat different dental conditions. Given the easy access to the oral cavity, the different cannabis formulations can be applied topically. The local application of low doses of cannabis has shown high effectiveness in treating different oral conditions, constituting a safe treatment with a low probability of generating unwanted systemic repercussions. It is currently being incorporated into conventional materials for dental use and hygiene in order to take advantage of its therapeutic effects. Cannabis has multiple uses in dentistry: as a component of mouthwashes and solutions for disinfecting root canals, in the treatment of oral anxiety disorders, as a complement in oncological therapies, as an analgesic to reduce inflammatory and neuropathic pain, as a muscle relaxant and chondroprotective to treat temporomandibular joint disorders and bruxism, as an osteomodulator for the treatment of pathologies that compromise bone integrity, such as periodontal disease and osteoporosis, and or bone healing associated with fractures, dental extractions and implants, and as immunomodulator with therapeutic potential to treat autoimmune pathologies such as rheumatic diseases. Local treatment with cannabis is effective, well tolerated by the patient and with few adverse effects. Local treatment with cannabis is effective, well tolerated by the patient and with few adverse effects. Therefore, it can be concluded that cannabis provides an enormous range of therapeutic possibilities to treat different dental conditions, although more scientific studies are still required to support its use in each particular pathophysiological situation (AU)
Sujets)
Humains , Dronabinol/usage thérapeutique , Cannabinoïdes/usage thérapeutique , Récepteurs de cannabinoïdes/usage thérapeutique , Hygiène buccodentaire/instrumentation , Maladies parodontales/traitement médicamenteux , Pulpite/traitement médicamenteux , Névralgie essentielle du trijumeau/traitement médicamenteux , Maladies osseuses/traitement médicamenteux , Algie faciale/traitement médicamenteux , Bruxisme/traitement médicamenteux , Tumeurs de la bouche/traitement médicamenteux , Rhumatismes/traitement médicamenteux , Administration par voie orale , Phobie des soins dentaires/traitement médicamenteux , Maladies de la bouche/traitement médicamenteuxRésumé
Introducción: los anti-TNF-α se asocian con mayor riesgo de desarrollar tuberculosis (TB). La prueba del derivado proteico purificado (purified protein derivative, PPD) se emplea para diagnosticar infección de tuberculosis latente (ITL). Se recomienda el cribado para TB previo al inicio de terapia anti-TNF-α y el seguimiento para evaluar la posible conversión de la PPD durante el tratamiento. El tratamiento de la ITL puede reducir el riesgo de desarrollar enfermedad activa en un 90%. Objetivos: actualmente los resultados de conversión de la PPD y su interpretación durante el tratamiento anti-TNF-α son variables, por tal motivo nos propusimos conocer la frecuencia de conversión de la PPD en este grupo de pacientes de nuestro medio. Materiales y métodos: realizamos un estudio descriptivo, observacional y retrospectivo que incluyó pacientes >18 años, diagnosticados con enfermedad reumática, tratados con anti-TNF-α. Resultados: se incluyeron 54 pacientes (46,7 ± a 12 años), de los cuales 36, presentaron diagnóstico de artritis reumatoidea, seis de artritis idiopática juvenil, cinco de espondilitis anquilosante, tres de artritis psoriásica, tres de uveítis y uno de queratitis intersticial. Los tratamientos fueron: 30 adalimumab, 17 certolizumab, siete etanercept, 44 metotrexato, 19 leflunomida, nueve hidroxicloroquina, dos sulfasalazina, dos azatioprina, uno mofetil micofenolato y glucocorticoides (28 de 54); la conversión de la PPD ocurrió en un solo paciente. Conclusiones: en el presente trabajo la seroconversión fue baja en contraste con otras series. La prueba de PPD es un método accesible, ampliamente disponible, adecuado y sensible para diagnosticar ITL.
Introduction: anti-TNF-α are associated with an increased risk of developing tuberculosis (TB). Purified protein derivative (PPD) is used to demonstrate a latent TB infection (LTBI). Screening is recommended for TB prior to the onset of anti-TNF-α and monitoring evaluating possible conversion of PPD during treatment. Treatment of LTBI can reduce the risk of active disease development by up to 90%. Objectives: currently the results of PPD conversion and its interpretation during anti-TNF-α treatment are variable and that is why we set out to know the frequency of conversion of PPD in this group of patients in our environment. Materials and methods: a descriptive, analytical, observational, retrospective study was conducted. Including patients >18 years old, diagnosed with rheumatic disease, treated with anti-TNF-α. Results: 54 patients were included (46.7 ± to 12 years), of which 36 presented a diagnosis of rheumatoid arthritis, 6 juvenile idiopathic arthritis, 5 ankylosing spondylitis, 3 psoriatic arthritis, 3 uveitis, 1 interstitial keratitis. The treatments were: 30 adalimumab, 17 certolizumab, 7 etanercept, 44 methotrexate, 19 leflunomide, 9 hydroxychloroquine, 2 sulfasalazine, 2 azathioprine, 1 mycophenolate mofetil and glucocorticoids (28/54). PPD conversion took place in 1 patient. Conclusions: in the present study, seroconversion was low in contrast to other series. The PPD test is an accessible, widely available, adequate and sensitive method for diagnosing LTBI, which the rheumatologist should use in his daily practice.
Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Jeune adulte , Test tuberculinique/méthodes , Rhumatismes/métabolisme , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Tuberculose latente/diagnostic , Rhumatismes/traitement médicamenteux , Études rétrospectives , Facteur de nécrose tumorale alpha/usage thérapeutique , Tuberculose latente/traitement médicamenteuxRésumé
ABSTRACT BACKGROUND: Rheumatic diseases (RDs) are a group of pathological conditions characterized by inflammation and functional disability. There is evidence suggesting that regular consumption of polyphenols has therapeutic effects capable of relieving RD symptoms. OBJECTIVE: To synthesize data from randomized controlled trials on administration of polyphenols and their effects on RD activity. DESIGN AND SETTING: Systematic review conducted at Universidade Federal de Ouro Preto, Minas Gerais, Brazil. METHODS: A systematic search was conducted in the databases PubMed (Medline), LILACS (BVS), IBECS (BVS), CUMED (BVS), BINACIS (BVS), EMBASE, Web of Science and Cochrane Library and in the grey literature. The present study followed a PRISMA-P checklist. RESULTS: In total, 646 articles were considered potentially eligible, of which 33 were then subjected to complete reading. Out of these, 17 randomized controlled trials articles were selected to form the final sample. Among these 17 articles, 64.71% assessed osteoarthritis (n = 11), 23.53% rheumatoid arthritis (n = 4), 5.88% rheumatoid arthritis and fibromyalgia (n = 1) and 5.88% osteoarthritis and rheumatoid (n = 1). Intake of polyphenol showed positive effects in most of the studies assessed (94.12%): it improved pain (64.70%) and inflammation (58.82%). CONCLUSION: Polyphenols are potential allies for treating RD activity. However, the range of polyphenol sources administered was a limitation of this review, as also was the lack of information about the methodological characteristics of the studies evaluated. Thus, further primary studies are needed in order to evaluate the effects of polyphenol consumption for reducing RD activity. SYSTEMATIC REVIEW REGISTER: PROSPERO - CRD42020145349.
Sujets)
Humains , Rhumatismes/traitement médicamenteux , Polyphénols/usage thérapeutique , Méta-analyse comme sujet , Revues systématiques comme sujet , InflammationRésumé
SUMMARY OBJECTIVES: Patients being treated with anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents were reported to have better prognosis related to COVID-19. We evaluated the factors affecting the frequency, clinical course, and outcome of COVID-19 in patients treated with anti-TNF-alpha agents. METHODS: Patients with rheumatoid diseases and chronic inflammatory bowel diseases treated with anti-TNF-alpha agents were evaluated retrospectively. The laboratory data in routine visits, frequency of COVID-19, pneumonia, hospitalization and/or intensive care unit (ICU) follow-up and, mortality were recorded. The factors related to COVID-19 frequency and clinical outcome were evaluated. RESULTS: A total of 324 patients (177 males [54.6%] and 147 females [45.4%], mean age: 45.3±12.16 years) was included in the study. In all, 44 (13.6%) patients had COVID-19; of these, 11 (25%) developed pneumonia, 7 (15.9%) were hospitalized, and 1 (2.3%) was followed up in ICU. There was no mortality. The patients with COVID-19 pneumonia were older (mean age: 52±11 years versus 41±12 years, p=0.01), had hypertension and coronary artery disease more frequently (5 cases [55.6%] versus 4 cases [44.4], p=0.02 and 2 cases [100%] versus 0 cases [0%], p=0.014, respectively), and lower eosinophil % (1.35±1.79% versus 2.3±1.45%, p=0.016). The diabetes mellitus was more frequent (66.7 versus 33.3%, p=0.013), and mean eosinophil % was lower among inpatients compared with outpatients (1.29±2.22% versus 2.19±1.37%, p=0.02). CONCLUSIONS: We concluded that the patients treated with anti-TNF-alpha agents having COVID-19 might have mild clinical course and better prognosis.
Sujets)
Humains , Mâle , Femelle , Adulte , Inhibiteurs du facteur de nécrose tumorale/administration et posologie , COVID-19/diagnostic , Pronostic , Maladies inflammatoires intestinales/traitement médicamenteux , Comorbidité , Rhumatismes/traitement médicamenteux , Études rétrospectives , Hospitalisation , Adulte d'âge moyenRésumé
Abstract Background: Hepatitis B virus (HBV) reactivation consequent to immunosuppressive therapy is an increasingly prevalent problem with serious clinical implications. Treatment with biologic agents conduces to the loss of protective antibody to HBV surface antigen (anti-HBs), which significantly increases the risk of HBV reactivation. Hence, we investigated the risk factors for losing anti-HBs in patients with rheumatic diseases and HBV surface antigen negative/anti-HBs positive (HBsAg-/anti-HBs+) serostatus during treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs). Methods: Using a nested case-control design, we prospectively enrolled patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis/psoriasis, or juvenile idiopathic arthritis, who were treated with biologic DMARDs at Changhua Christian Hospital, Taiwan, from January 2013 to June 2019 and had HBsAg-/anti-HBs+ serostatus; the analytic sample excluded all patients with HBsAg+ or anti-HBs- serostatus. Anti-HBs titers were monitored 6-monthly and cases were defined as anti-HBs < 10 mIU/ml during follow-up. Cases were matched one- to-all with controls with anti-HBs ≥ 10 mIU/ml on the same ascertainment date and equivalent durations of biologic DMARDs treatment (control patients could be resampled and could also become cases during follow-up). Between-group characteristics were compared and risk factors for anti-HBs loss were investigated by conditional logistic regression analyses. Results: Among 294 eligible patients, 23 cases were matched with 311 controls. The incidence of anti-HBs loss was ∼ 2.7%/person-year during biologic DMARDs treatment. Besides lower baseline anti-HBs titer (risk ratio 0.93, 95% CI 0.89-0.97), cases were significantly more likely than controls to have diabetes mellitus (risk ratio 4.76, 95% CI 1.48-15.30) and chronic kidney disease (risk ratio 14.00, 95% CI 2.22-88.23) in univariate analysis. Risk factors remaining significantly associated with anti-HBs loss in multivariate analysis were lower baseline anti-HBs titer (adjusted risk ratio 0.93, 95% CI 0.88-0.97) and chronic kidney disease (adjusted risk ratio 45.68, 95% CI 2.39-871.5). Conclusions: Besides lower baseline anti-HBs titer, chronic kidney disease also strongly predicts future anti-HBs negativity in patients with HBsAg-/anti-HBs+ serostatus who receive biologic DMARDs to treat rheumatic diseases. Patients with low anti-HBs titer (≤ 100 mIU/ml) and/or chronic kidney disease should be monitored during biologic DMARDs therapy, to enable timely prophylaxis to preempt potential HBV reactivation.
Sujets)
Humains , Produits biologiques , Virus de l'hépatite B , Rhumatismes , Antirhumatismaux , Antigènes de surface du virus de l'hépatite B , Produits biologiques/usage thérapeutique , Études cas-témoins , Virus de l'hépatite B/immunologie , Rhumatismes/sang , Rhumatismes/traitement médicamenteux , Études prospectives , Facteurs de risque , Antirhumatismaux/usage thérapeutique , Antigènes de surface du virus de l'hépatite B/sangRésumé
The ongoing pandemic in Singapore is part of a global pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To control the spread of COVID-19 and prevent the healthcare system from being overwhelmed, 'circuit breaker' measures were introduced between 7 April and 1 June 2020 in Singapore. There is thus a crucial need for innovative approaches to the provision and delivery of healthcare in the context of safe-distancing by harnessing telemedicine, especially for patients with chronic diseases who have traditionally been managed in tertiary institutions. We present a summary of how the Virtual Monitoring Clinic has benefited the practice of our outpatient rheumatology service during the COVID-19 pandemic. The virtual consultations address the need for safe-distancing by limiting face-to-face appointments and unnecessary exposure of patients to the hospital where feasible. This approach ensures that the patients are monitored appropriately for drug toxicities and side-effects, maintained on good disease control, and provided with patient education.
Sujets)
Humains , Soins ambulatoires/méthodes , Antirhumatismaux/usage thérapeutique , COVID-19 , Prestations des soins de santé , Infirmières praticiennes , Pharmaciens , Rhumatismes/traitement médicamenteux , Rhumatologie/méthodes , SARS-CoV-2 , Singapour , Télémédecine/organisation et administration , Centres de soins tertiairesRésumé
Abstract Hydroxychloroquine and chloroquine, also known as antimalarial drugs, are widely used in the treatment of rheumatic diseases and have recently become the focus of attention because of the ongoing COVID-19 pandemic. Rheumatologists have been using antimalarials to manage patients with chronic immune-mediated inflammatory rheumatic diseases for decades. It is an appropriate time to review their immunomodulatory and anti-inflammatory mechanisms impact on disease activity and survival of systemic lupus erythematosus patient, including antiplatelet effect, metabolic and lipid benefits. We also discuss possible adverse effects, adding a practical and comprehensive approach to monitoring rheumatic patients during treatment with these drugs.(AU)
Sujets)
Humains , Chloroquine/usage thérapeutique , Rhumatismes/traitement médicamenteux , Hydroxychloroquine/usage thérapeutique , Chloroquine/pharmacologie , Hydroxychloroquine/pharmacologieRésumé
Desde fines del 2019 enfrentamos el brote de una nueva infección por coronavirus llamada COVID-19, que rápidamente se transformó en una pandemia y llegó a nuestro país a principios del 2020. Esto ha traído muchas preguntas y desafíos, específicamente en nuestros pacientes con enfermedades autoinmunes, que tienen tradicionalmente mayor riesgo de contraer infecciones y de complicarse por estas. Por otra parte, en el tratamiento actual del síndrome respiratorio agudo severo causado por el coronavirus SARS-CoV-2 se están usando e investigando varios medicamentos inmunosupresores e inmunomoduladores del arsenal reumatológico para controlar la respuesta inmune exagerada que se produce en el huésped en el COVID-19 grave. En esta revisión analizamos la literatura existente hasta el momento sobre pacientes reumatológicos y COVID-19, medicamentos reumatológicos en investigación y en uso para el manejo de la infección por SARS-CoV-2, y resumimos ciertas recomendaciones de manejo específicas para nuestros pacientes.
Since the end of 2019 we have been facing the outbreak of a new coronavirus infection called COVID-19, which quickly turned into a pandemic arriving in Chile in early 2020. This has brought with it many questions and challenges, specifically for our patients with autoimmune diseases, which have an increased risk of infections due to their disease and the use of immunosuppresant and corticosteroid drugs. On the other hand, in the current treatment of severe acute respiratory syndrome caused by the SARS-CoV-2 coronavirus, several immunosuppressive and immunomodulatory drugs in the rheumatologic arsenal are being used and investigated to control the exaggerated immune response that occurs in the host in serious COVID -19 cases. In this review we investigated the literature to date on rheumatology patients and COVID-19, rheumatology drugs under investigation and in use for the management of SARS-CoV-2 infection, and have summarized certain specific management recommendations for our patients
Sujets)
Humains , Pneumopathie virale , Rhumatismes/traitement médicamenteux , Infections à coronavirus/thérapie , Immunosuppresseurs/effets indésirables , Maladies auto-immunes , Biothérapie , Chloroquine/usage thérapeutique , Hormones corticosurrénaliennes/usage thérapeutique , Pneumopathies interstitielles/complications , Pandémies , Betacoronavirus , Hydroxychloroquine/usage thérapeutique , Lupus érythémateux disséminé/complicationsRésumé
Las pandemias han sido inherentes a la presencia del ser humano en el planeta tierra. Desde el inicio del siglo actual ha destacado la aparición de varias enfermedades virales de relevancia mundial, siendo la enfermedad provocada por el SARS-CoV2 la más importante de ellas (COVID-19). La comunidad científica y los distintos países no estaban preparados para un desafío de esta envergadura. Desde el punto de vista de la reumatología se desconoce las implicancias de este nuevo virus en los pacientes con enfermedades reumatológicas y sus tratamientos. Como reumatólogos nos encontramos frente a una oportunidad única de participar activamente para disipar esas interrogantes.
Pandemics have been inherent to our condition as inhabitants on this planet. Several viral diseases of worldwide concern have been reported since beginning of the actual century, being COVID-19 due to SARS-CoV2 the most important. The scientific community and the different countries have not been prepared for this kind of challenge. The potential issues about this novel virus and rheumatologic patients and their treatments are unknown. As rheumatologist we can actively participate in dissipate those questions.
Sujets)
Humains , Pneumopathie virale , Rhumatismes/traitement médicamenteux , Infections à coronavirus/traitement médicamenteux , Pandémies , Betacoronavirus , Hydroxychloroquine/usage thérapeutiqueRésumé
Las terapias biológicas son una herramienta terapéutica fundamental en cierto grupo de pacientes, sin embargo, su seguridad en el embarazo y lactancia no está aún dilucidada. El objetivo de esta revisión es actualizar los conocimientos y recomendaciones respecto al uso de fármacos biológicos durante el embarazo y lactancia. En relación al embarazo, las recomendaciones actuales sugieren que los anti TNF se podrían continuar o mantener hasta el segundo trimestre del embarazo. La terapia anti CD20 (Rituximab) y otros biológicos se recomiendan suspender en el embarazo. Durante la lactancia, se puede iniciar o continuar cualquier terapia biológica. En la primera mitad del embarazo se pueden utilizar algunos biológicos con relativo buen perfil de seguridad y en la lactancia la evidencia sugiere que no producirían mayor riesgo en el niño. Sería ideal contar con estudios randomizados controlados, pero esto podría generar un dilema ético.
Biological therapies are a fundamental therapeutic tool in a certain group of patients. However, the safety of these drugs during pregnancy and lactation remains unclear. Current recommendations regarding anti TNF use during pregnancy suggest these could be maintained until the second trimester of pregnancy. Anti CD20 therapy (Rituximab) and other biologics should not be used in pregnancy. Patients can safely initiate or continue to use biological therapy during lactation. Some biologicals are relatively safe to use during pregnancy and recent studies show that they can be used during lactation without being a major threat to the child. It would be ideal to have randomized controlled studies, but this could create an ethical dilemma.
Sujets)
Humains , Femelle , Grossesse , Biothérapie , Lactation , Rhumatismes/traitement médicamenteux , Facteur de nécrose tumorale alpha/usage thérapeutique , Produits biologiques/usage thérapeutique , Antirhumatismaux/usage thérapeutiqueRésumé
El Citomegalovirus es un microorganismo capaz de generar infecciones severas en pacientes inmunosuprimidos. Existe abundante información respecto a la infección en pacientes inmunosuprimidos por VIH o en relación a trasplante de órganos sólidos o hematopoyéticos. No ocurre lo mismo con los pacientes portadores de enfermedades autoinmunes. Si bien la clínica puede ser inespecífica y dificultar la sospecha diagnóstica, la clave está en determinar al paciente de riesgo para la infección y así realizar un diagnóstico precoz. Se presenta el caso de una mujer de 56 años, portadora de una polimiositis de difícil tratamiento, que en un contexto de terapia en base a corticoides e inmunosupresores (azatioprina y metotrexato), desarrolla cuadro febril asociado a fatiga, cuyo estudio concluyó una infección por Citomegalovirus, tratado exitosamente con Valganciclovir.
Cytomegalovirus is a microorganism associated with severe infections in immunosuppressed patients. There is abundant information regarding infection in HIV immunosuppressed patients or in relation to solid or hematopoietic organ transplantation. The same does not happen with patients with rheumatic diseases. Although the clinic can be nonspecific and hinder diagnostic suspicion, the key is to determine the patient at risk for the infection and thus make an early diagnosis. We present a case of a 56-year-old woman with a difficult-to-treat polymyositis, who, in a context of corticosteroid and immunosuppressive agents (azathioprine and methotrexate), develops a fever associated with fatigue, whose study con-cluded an infection due to Cytomegalovirus, successfully treated with Valganci-clovir.
Sujets)
Humains , Femelle , Adulte d'âge moyen , Rhumatismes/complications , Immunosuppression thérapeutique/effets indésirables , Cytomegalovirus/immunologie , Rhumatismes/traitement médicamenteux , Polymyosite , Infections à cytomégalovirus , Immunosuppresseurs/usage thérapeutiqueRésumé
Introducción: la artritis idiopática juvenil es una afección inflamatoria y sistémica que afecta a pacientes menores de 18 años. Engloba una serie de manifestaciones clínicas que en edad adulta tiene nombre común como enfermedades ya establecida; sin embargo, todas ellas se engloban bajo este término en niños y adolescentes. Todas sus formas clínicas tienen como elemento común la presencia de un cuadro inflamatorio que genera artritis; según la característica de la toma articular y la presencia de otras manifestaciones, es que se definen las formas clínicas de la enfermedad. Objetivo: dar a conocer los elementos clínicos y de laboratorio que permiten llegar al diagnóstico de la artritis idiopática juvenil en la atención primaria de salud. Caso clínico: se presenta el caso de una paciente de 9 años de edad que presenta manifestaciones clínicas y de laboratorio que permiten realizar el diagnóstico de artritis idiopática juvenil. Conclusiones: las enfermedades reumáticas afectan generalmente a pacientes adultos, con predominio de edades avanzadas, sin embargo, resulta importante conocer los elementos diagnósticos de cada uno de ellos para poder detectar su aparición en edades tempranas de la vida(AU)
Introduction: juvenile idiopathic arthritis is an inflammatory and systemic condition that affects patients under 18 years of age. It encompasses a series of clinical manifestations that in adult age has a common name as established diseases; however, all of them are included under this term in children and adolescents. All its clinical forms have as a common element the presence of an inflammatory condition that generates arthritis; According to the characteristic of the joint taking and the presence of other manifestations, it is that the clinical forms of the disease are defined. Objective: to present the clinical and laboratory elements that allow to reach the diagnosis of juvenile idiopathic arthritis in primary health care. Clinical case: the case of a 9-year-old patient with clinical and laboratory manifestations that allow the diagnosis of juvenile idiopathic arthritis is presented. Conclusions: rheumatic diseases generally affect adult patients, with a predominance of advanced ages; however, it is important to know the diagnostic elements of each of them in order to detect their appearance at early ages of life(AU)
Sujets)
Humains , Femelle , Enfant , Soins de santé primaires/méthodes , Arthrite juvénile/diagnostic , Rhumatismes/traitement médicamenteuxRésumé
ABSTRACT Most people infected by Mycobacterium tuberculosis (Mtb) do not have any signs or disease symptoms, a condition known as latent tuberculosis infection (LTBI). The introduction of biological agents, mainly tumor necrosis factor (TNF) inhibitors, for the treatment of immune-mediated diseases such as Rheumatoid Arthritis (RA) and other rheumatic diseases, increased the risk of reactivation of LTBI, leading to development of active TB. Thus, this review will approach the aspects related to LTBI in patients with rheumatologic diseases, especially those using iTNF drugs. For this purpose it will be considered the definition and prevalence of LTBI, mechanisms associated with diseases and medications in use, criteria for screening, diagnosis and treatment. Considering that reactivation of LTBI accounts for a large proportion of the incidence of active TB, adequate diagnosis and treatment are crucial, especially in high-risk groups such as patients with rheumatologic diseases.
RESUMO A maioria das pessoas infectadas por Mycobacterium tuberculosis (Mtb) não possui sinais ou sintomas da doença, quadro conhecido como infecção latente por tuberculose (ILTB). A introdução de agentes biológicos, sobretudo inibidores do fator de necrose tumoral (iTNF), para o tratamento de doenças imunomediadas, como artrite reumatoide (AR) e outras doenças reumatológicas, aumentou o risco de reativação de ILTB, levando ao desenvolvimento de tuberculose (TB) ativa. Assim, esta revisão abordará os aspectos relacionados à ILTB em pacientes com doenças reumatológicas, especialmente naqueles em uso de medicamentos iTNF. Para tanto, serão considerados a definição e a prevalência de ILTB, os mecanismos associados às doenças e às medicações em uso, bem como os critérios para rastreamento, diagnóstico e tratamento da ILTB. Como a reativação da ILTB é responsável pela grande proporção de casos de TB ativa, o diagnóstico e o tratamento adequados são cruciais, principalmente em grupos de alto risco, como os pacientes com doenças reumatológicas.
Sujets)
Humains , Rhumatismes/complications , Rhumatismes/traitement médicamenteux , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Tuberculose latente/étiologie , Test tuberculinique , Facteurs de risque , Antirhumatismaux/effets indésirables , Tuberculose latente/diagnostic , Tuberculose latente/traitement médicamenteux , Tests de libération d'interféron-gammaRésumé
Abstract Hydroxychloroquine is widely used by rheumatologists for the treatment of various diseases, such as systemic lupus erythematosus and rheumatoid arthritis because of its safety and low cost. However, it can cause retinal abnormalities. Until today, there is no Brazilian protocol for screening for retinal changes in these patients. We reviewed the medical records and optical coherence tomography of all patients who had attended at Hychloroquine Ambulatory of HFSE, in the period from March/ 2015 until November/2016.
Resumo A Hidroxicloroquina é amplamente utilizada por reumatologistas para o tratamento de várias condições, como os lúpus eritematoso sistêmico e artrite reumatoide, pelo seu baixo custo e relativa segurança. Porém, esta droga pode causar danos à retina. Até o presente momento, não há protocolo brasileiro para o screening de alterações retinianas devido ao uso desta medicação. Foi realizada revisão de prontuário e análise de imagens de tomografia de coerência óptica de pacientes atendidos no período de Março de 2015 a Novembro de 2016 no ambulatório de Hidroxicloroquina do Hospital Federal dos Servidores do Estado do Rio de Janeiro.
Sujets)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sujet âgé , Sujet âgé de 80 ans ou plus , Rétinopathies/induit chimiquement , Rhumatismes/traitement médicamenteux , Antirhumatismaux/effets indésirables , Hydroxychloroquine/effets indésirables , Rétine/effets des médicaments et des substances chimiques , Rétinopathies/imagerie diagnostique , Dossiers médicaux , Études transversales , Tomographie par cohérence optiqueRésumé
: relacionar el uso de hidroxicloroquina con la presencia de retinopatía en pacientes reumatológicos. Métodos: se realizó un estudio retrospectivo y descriptivo, de revisión de historias clínicas de pacientes reumatológicos en tratamiento con hidroxicloroquina. Se seleccionaron aquellos con evaluación oftalmológica previa al inicio del tratamiento y estudios como la OCT-SD. Se recolectaron variables clínico epidemiológicas, cálculo de dosis diaria y acumulada del fármaco, y duración del tratamiento. Resultados: se revisaron 150 historias, de las cuales 47 cumplieron con los criterios de inclusión; 44 (93,6%) eran del género femenino y 3 (6,4%) del género masculino. La edad promedio fue de 47 ± 14 años. La hipertensión arterial fue la comorbilidad más frecuente. La patología reumatológica más frecuente fue el Lupus (53,2%). La dosis diaria de hidroxicloroquina fue ≤ 6,5 mg/kg/día en los 47 pacientes; el tiempo promedio de consumo fue de 5 años; y la dosis acumulada promedio fue de 498,5 ± 503,68 gramos. Se detectó toxicidad retiniana en 18 pacientes (38,3%), de los cuales: 17(36,2%) tuvo daño precoz y 1 (2,1%) daño moderado. Se observó relación estadística significativa entre toxicidad retiniana y dosis acumulada menores a 1.000 gramos (p= 0,032) y un tiempo de consumo mayor o igual a 5 años (p = 0,045) Conclusiones: las alteraciones iniciales en las capas externas de la retina ayudan a la detección precoz de toxicidad retiniana por hidroxicloroquina, siendo la OCT-SD un método sensible y fácil de realizar en la práctica clínica(AU)
To establish the relationship between the use of hydroxychloroquine and retinopathies in rheumatologic patients. Methods: This is a retrospective, descriptive study of the medical charts of rheumatologic patients' who were receiving hydroxychloroquine. We selected patients previously seen in ophthalmologic services, and ophthalmologic coherence tomography (SD OCT) had been realized. We collected clinical and epidemiologic variables such as daily doses, accumulated doses and prescription duration. Results: we selected 47 medical charts; the female gender is 44 and three gender male. Mean age was 47 +14 years.Hypertension was the most frequent comorbidity.Lupus was the most frequent rheumatologic illness.Hydroxychloroquine daily dose was < 6.5 mg/Kg/day and treatment`s mean duration was 5 years; average accumulated dosage was 498.5 + 503.68 grs. We established retinal toxicity in 18 patients (38.3%), in which 17 (36.2%) had early damage, and 1(2.1%) had moderated damage. There was a statistical correlation between retinal toxicity and accumulated doses of less than 1.000 grs. (p: 0.032) as well as with time of use > 5 years (p:0.045) Conclusions: Early alterations of retinal superficial layers help in the detection of early retinal toxicity due to hydroxychloroquine use. OCTSD is a feasible and sensible study in daily medical practice(AU)
Sujets)
Humains , Mâle , Femelle , Lupus érythémateux cutané/traitement médicamenteux , Rhumatismes/traitement médicamenteux , Hydroxychloroquine/administration et posologie , Hydroxychloroquine/effets indésirables , Hypertension artérielle/physiopathologie , Rétinopathie hypertensive , Médecine interneRésumé
ResumenEn los últimos 15 años se han desarrollado terapias y esquemas terapéuticos para inducir la remisión a la gran mayoría de enfermedades reumatológicas. La mejoría clínica lograda se consigue a expensas de una inmunosupresión más agresiva y específica, lo que conlleva un aumento en el riesgo de infecciones. La principal causa de muerte de las enfermedades autoinmunes, en los primeros 5 años de evolución, es la infección secundaria a la inmunosupresión. El objetivo del presente trabajo fue elaborar un documento de consenso con el afán de reducir este riesgo, basado en la mejor evidencia médica disponible, utilizando los recursos disponibles en el hospital para disminuir la morbimortalidad de los pacientes que reciben estas terapias. Contar con un documento de consenso permitirá minimizar los efectos secundarios y mejorar la acción terapéutica, con mayores oportunidades de remisión y una más adecuada utilización del recurso institucional.
AbstractIn the last 15 years therapies and therapeutic schemes have been developed to induce remission to the vast majority of rheumatologic diseases. The clinical improvement achieved is at the cost of a more aggressive and specific immunosuppression, which leads to an increase in the risk of infections. The main cause of death of autoimmune diseases in the first 5 years of evolution is infection secondary to immunosuppression. The objective of the present study was to develop a consensus document with the aim of reducing this risk of infection, based on the best available medical evidence, using the resources available in our hospital to reduce the morbidity and mortality of patients receiving these therapies. Having a consensus document will allow us to minimize side effects and improve therapeutic action with greater opportunities for referral and better utilization of institutional resources.
Sujets)
Humains , Biothérapie/effets indésirables , Rhumatismes/traitement médicamenteux , Rhumatismes/thérapie , Rhumatologie/tendancesRésumé
Rheumatic diseases are very prevalent, affecting about 7 million people in North America; they affect the musculoskeletal system, often with systemic involvement and potential for serious consequences and limitation on quality of life. Clinical treatment is usually long-term and includes drugs that are considered either simple or complex and are occasionally unknown to many health professionals who do not know how to manage these patients in emergency units and surgical wards. Thus, it is important for clinicians, surgeons and anesthesiologists who are involved with rheumatic patients undergoing surgery to know the basic principles of therapy and perioperative management. This study aims to do a review of the perioperative management of the most commonly used drugs in rheumatologic patients. Manuscripts used in this review were identified by surveying MEDLINE, LILACS, EMBASE, and COCHRANE databases and included studies containing i) the perioperative management of commonly used drugs in patients with rheumatic diseases: and ii) rheumatic diseases. They are didactically discussed according to the mechanism of action and pharmacokinetics; and perioperative management. In total, 259 articles related to the topic were identified. Every medical professional should be aware of the types of drugs that are appropriate for continuous use and should know the various effects of these drugs before indicating surgery or assisting a rheumatic patient postoperatively. This information could prevent possible complications that could affect a wide range of patients.